Biopharmaceutical Comprehensive Study by Type (Monoclonal Antibodies, Erythropoietin (EPO), Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons (IFNs), Human Growth Hormones, Other Biopharmaceuticals), Application (Diseases (Inflammatory and infectious, Cardiovascular and Neurological), Disorders (Autoimmune, Metabolic and Hormonal), Other), Production (Microbial Cells, Mammalian Cells, Plant Cells, Transgenics) Players and Region - Global Market Outlook to 2026

Biopharmaceutical Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 8.6%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
The Global Biopharmaceutical market presents a comprehensive analysis of the Biopharmaceutical market by product type (Monoclonal Antibodies, Erythropoietin (EPO), Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons (IFNs), Human Growth Hormones and Other Biopharmaceuticals), by end-user/application (Diseases [Inflammatory and infectious, Cardiovascular and Neurological], Disorders [Autoimmune, Metabolic and Hormonal] and Other), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up.

Market Drivers
  • Increasing acceptance for biopharmaceuticals,
  • The ability of biopharmaceuticals to treat previously untreatable diseases
  • Huge market demand

Market Trend
  • Technological advancements in biopharmaceuticals have transformed treatment options for many diseases

Restraints
  • Increasing demand for affordable biopharmaceuticals
  • High-end manufacturing requirements
  • Complicated and cumbersome regulatory requirements
  • Side effects of biopharmaceuticals


Geographic Segmentation and Analysis
This section of our report presents a realistic picture of the Global Biopharmaceutical industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the United States holds majority of market share of the Biopharmaceutical
The regional segmentation covered in this report are:
South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Erythropoietin (EPO)
  • Biotech Vaccines
  • Recombinant Human (RH) Insulin
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Interferons (IFNs)
  • Human Growth Hormones
  • Other Biopharmaceuticals
By Application
  • Diseases [Inflammatory and infectious, Cardiovascular and Neurological]
  • Disorders [Autoimmune, Metabolic and Hormonal]
  • Other
By Production
  • Microbial Cells
  • Mammalian Cells
  • Plant Cells
  • Transgenics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing acceptance for biopharmaceuticals,
      • 3.2.2. The ability of biopharmaceuticals to treat previously untreatable diseases
      • 3.2.3. Huge market demand
    • 3.3. Market Challenges
      • 3.3.1. Increasing demand for affordable biopharmaceuticals
      • 3.3.2. A very controversial method and is still under the trial phase
      • 3.3.3. Entry of low cost biosimilars of existing biopharmaceuticals
      • 3.3.4. High costs associated with drug development
    • 3.4. Market Trends
      • 3.4.1. Technological advancements in biopharmaceuticals have transformed treatment options for many diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biopharmaceutical, by Type, Application, Production and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Biopharmaceutical (Value)
      • 5.2.1. Global Biopharmaceutical by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Erythropoietin (EPO)
        • 5.2.1.3. Biotech Vaccines
        • 5.2.1.4. Recombinant Human (RH) Insulin
        • 5.2.1.5. Granulocyte Colony-Stimulating Factor (G-CSF)
        • 5.2.1.6. Interferons (IFNs)
        • 5.2.1.7. Human Growth Hormones
        • 5.2.1.8. Other Biopharmaceuticals
      • 5.2.2. Global Biopharmaceutical by: Application (Value)
        • 5.2.2.1. Diseases [Inflammatory and infectious, Cardiovascular and Neurological]
        • 5.2.2.2. Disorders [Autoimmune, Metabolic and Hormonal]
        • 5.2.2.3. Other
      • 5.2.3. Global Biopharmaceutical by: Production (Value)
        • 5.2.3.1. Microbial Cells
        • 5.2.3.2. Mammalian Cells
        • 5.2.3.3. Plant Cells
        • 5.2.3.4. Transgenics
      • 5.2.4. Global Biopharmaceutical Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Biopharmaceutical: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis A.G. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biogen Idec (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lily & Co. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Biopharmaceutical Sale, by Type, Application, Production and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Biopharmaceutical (Value)
      • 7.2.1. Global Biopharmaceutical by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Erythropoietin (EPO)
        • 7.2.1.3. Biotech Vaccines
        • 7.2.1.4. Recombinant Human (RH) Insulin
        • 7.2.1.5. Granulocyte Colony-Stimulating Factor (G-CSF)
        • 7.2.1.6. Interferons (IFNs)
        • 7.2.1.7. Human Growth Hormones
        • 7.2.1.8. Other Biopharmaceuticals
      • 7.2.2. Global Biopharmaceutical by: Application (Value)
        • 7.2.2.1. Diseases [Inflammatory and infectious, Cardiovascular and Neurological]
        • 7.2.2.2. Disorders [Autoimmune, Metabolic and Hormonal]
        • 7.2.2.3. Other
      • 7.2.3. Global Biopharmaceutical by: Production (Value)
        • 7.2.3.1. Microbial Cells
        • 7.2.3.2. Mammalian Cells
        • 7.2.3.3. Plant Cells
        • 7.2.3.4. Transgenics
      • 7.2.4. Global Biopharmaceutical Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biopharmaceutical: by Type(USD Million)
  • Table 2. Biopharmaceutical Monoclonal Antibodies , by Region USD Million (2015-2020)
  • Table 3. Biopharmaceutical Erythropoietin (EPO) , by Region USD Million (2015-2020)
  • Table 4. Biopharmaceutical Biotech Vaccines , by Region USD Million (2015-2020)
  • Table 5. Biopharmaceutical Recombinant Human (RH) Insulin , by Region USD Million (2015-2020)
  • Table 6. Biopharmaceutical Granulocyte Colony-Stimulating Factor (G-CSF) , by Region USD Million (2015-2020)
  • Table 7. Biopharmaceutical Interferons (IFNs) , by Region USD Million (2015-2020)
  • Table 8. Biopharmaceutical Human Growth Hormones , by Region USD Million (2015-2020)
  • Table 9. Biopharmaceutical Other Biopharmaceuticals , by Region USD Million (2015-2020)
  • Table 10. Biopharmaceutical: by Application(USD Million)
  • Table 11. Biopharmaceutical Diseases [Inflammatory and infectious, Cardiovascular and Neurological] , by Region USD Million (2015-2020)
  • Table 12. Biopharmaceutical Disorders [Autoimmune, Metabolic and Hormonal] , by Region USD Million (2015-2020)
  • Table 13. Biopharmaceutical Other , by Region USD Million (2015-2020)
  • Table 14. Biopharmaceutical: by Production(USD Million)
  • Table 15. Biopharmaceutical Microbial Cells , by Region USD Million (2015-2020)
  • Table 16. Biopharmaceutical Mammalian Cells , by Region USD Million (2015-2020)
  • Table 17. Biopharmaceutical Plant Cells , by Region USD Million (2015-2020)
  • Table 18. Biopharmaceutical Transgenics , by Region USD Million (2015-2020)
  • Table 19. South America Biopharmaceutical, by Country USD Million (2015-2020)
  • Table 20. South America Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 21. South America Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 22. South America Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 23. Brazil Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 24. Brazil Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 25. Brazil Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 26. Argentina Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 27. Argentina Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 28. Argentina Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 29. Rest of South America Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 30. Rest of South America Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 31. Rest of South America Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 32. Asia Pacific Biopharmaceutical, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 34. Asia Pacific Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 36. China Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 37. China Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 38. China Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 39. Japan Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 40. Japan Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 41. Japan Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 42. India Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 43. India Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 44. India Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 45. South Korea Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 46. South Korea Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 47. South Korea Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 48. Taiwan Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 49. Taiwan Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 50. Taiwan Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 51. Australia Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 52. Australia Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 53. Australia Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 57. Europe Biopharmaceutical, by Country USD Million (2015-2020)
  • Table 58. Europe Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 59. Europe Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 60. Europe Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 61. Germany Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 62. Germany Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 63. Germany Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 64. France Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 65. France Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 66. France Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 67. Italy Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 68. Italy Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 69. Italy Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 70. United Kingdom Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 71. United Kingdom Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 72. United Kingdom Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 73. Netherlands Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 74. Netherlands Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 75. Netherlands Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 76. Rest of Europe Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 77. Rest of Europe Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 78. Rest of Europe Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 79. MEA Biopharmaceutical, by Country USD Million (2015-2020)
  • Table 80. MEA Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 81. MEA Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 82. MEA Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 83. Middle East Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 84. Middle East Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 85. Middle East Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 86. Africa Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 87. Africa Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 88. Africa Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 89. North America Biopharmaceutical, by Country USD Million (2015-2020)
  • Table 90. North America Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 91. North America Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 92. North America Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 93. United States Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 94. United States Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 95. United States Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 96. Canada Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 97. Canada Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 98. Canada Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 99. Mexico Biopharmaceutical, by Type USD Million (2015-2020)
  • Table 100. Mexico Biopharmaceutical, by Application USD Million (2015-2020)
  • Table 101. Mexico Biopharmaceutical, by Production USD Million (2015-2020)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Biopharmaceutical: by Type(USD Million)
  • Table 112. Biopharmaceutical Monoclonal Antibodies , by Region USD Million (2021-2026)
  • Table 113. Biopharmaceutical Erythropoietin (EPO) , by Region USD Million (2021-2026)
  • Table 114. Biopharmaceutical Biotech Vaccines , by Region USD Million (2021-2026)
  • Table 115. Biopharmaceutical Recombinant Human (RH) Insulin , by Region USD Million (2021-2026)
  • Table 116. Biopharmaceutical Granulocyte Colony-Stimulating Factor (G-CSF) , by Region USD Million (2021-2026)
  • Table 117. Biopharmaceutical Interferons (IFNs) , by Region USD Million (2021-2026)
  • Table 118. Biopharmaceutical Human Growth Hormones , by Region USD Million (2021-2026)
  • Table 119. Biopharmaceutical Other Biopharmaceuticals , by Region USD Million (2021-2026)
  • Table 120. Biopharmaceutical: by Application(USD Million)
  • Table 121. Biopharmaceutical Diseases [Inflammatory and infectious, Cardiovascular and Neurological] , by Region USD Million (2021-2026)
  • Table 122. Biopharmaceutical Disorders [Autoimmune, Metabolic and Hormonal] , by Region USD Million (2021-2026)
  • Table 123. Biopharmaceutical Other , by Region USD Million (2021-2026)
  • Table 124. Biopharmaceutical: by Production(USD Million)
  • Table 125. Biopharmaceutical Microbial Cells , by Region USD Million (2021-2026)
  • Table 126. Biopharmaceutical Mammalian Cells , by Region USD Million (2021-2026)
  • Table 127. Biopharmaceutical Plant Cells , by Region USD Million (2021-2026)
  • Table 128. Biopharmaceutical Transgenics , by Region USD Million (2021-2026)
  • Table 129. South America Biopharmaceutical, by Country USD Million (2021-2026)
  • Table 130. South America Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 131. South America Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 132. South America Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 133. Brazil Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 134. Brazil Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 135. Brazil Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 136. Argentina Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 137. Argentina Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 138. Argentina Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 139. Rest of South America Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 140. Rest of South America Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 141. Rest of South America Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 142. Asia Pacific Biopharmaceutical, by Country USD Million (2021-2026)
  • Table 143. Asia Pacific Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 144. Asia Pacific Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 145. Asia Pacific Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 146. China Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 147. China Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 148. China Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 149. Japan Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 150. Japan Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 151. Japan Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 152. India Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 153. India Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 154. India Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 155. South Korea Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 156. South Korea Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 157. South Korea Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 158. Taiwan Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 159. Taiwan Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 160. Taiwan Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 161. Australia Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 162. Australia Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 163. Australia Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 166. Rest of Asia-Pacific Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 167. Europe Biopharmaceutical, by Country USD Million (2021-2026)
  • Table 168. Europe Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 169. Europe Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 170. Europe Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 171. Germany Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 172. Germany Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 173. Germany Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 174. France Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 175. France Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 176. France Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 177. Italy Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 178. Italy Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 179. Italy Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 180. United Kingdom Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 181. United Kingdom Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 182. United Kingdom Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 183. Netherlands Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 184. Netherlands Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 185. Netherlands Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 186. Rest of Europe Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 187. Rest of Europe Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 188. Rest of Europe Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 189. MEA Biopharmaceutical, by Country USD Million (2021-2026)
  • Table 190. MEA Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 191. MEA Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 192. MEA Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 193. Middle East Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 194. Middle East Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 195. Middle East Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 196. Africa Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 197. Africa Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 198. Africa Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 199. North America Biopharmaceutical, by Country USD Million (2021-2026)
  • Table 200. North America Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 201. North America Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 202. North America Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 203. United States Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 204. United States Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 205. United States Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 206. Canada Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 207. Canada Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 208. Canada Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 209. Mexico Biopharmaceutical, by Type USD Million (2021-2026)
  • Table 210. Mexico Biopharmaceutical, by Application USD Million (2021-2026)
  • Table 211. Mexico Biopharmaceutical, by Production USD Million (2021-2026)
  • Table 212. Research Programs/Design for This Report
  • Table 213. Key Data Information from Secondary Sources
  • Table 214. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biopharmaceutical: by Type USD Million (2015-2020)
  • Figure 5. Global Biopharmaceutical: by Application USD Million (2015-2020)
  • Figure 6. Global Biopharmaceutical: by Production USD Million (2015-2020)
  • Figure 7. South America Biopharmaceutical Share (%), by Country
  • Figure 8. Asia Pacific Biopharmaceutical Share (%), by Country
  • Figure 9. Europe Biopharmaceutical Share (%), by Country
  • Figure 10. MEA Biopharmaceutical Share (%), by Country
  • Figure 11. North America Biopharmaceutical Share (%), by Country
  • Figure 12. Global Biopharmaceutical share by Players 2020 (%)
  • Figure 13. Global Biopharmaceutical share by Players (Top 3) 2020(%)
  • Figure 14. Global Biopharmaceutical share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis A.G. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis A.G. (Switzerland) Revenue: by Geography 2020
  • Figure 18. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 20. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 22. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 24. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Biogen Idec (United States) Revenue, Net Income and Gross profit
  • Figure 27. Biogen Idec (United States) Revenue: by Geography 2020
  • Figure 28. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 30. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 31. AbbVie (United States) Revenue: by Geography 2020
  • Figure 32. Eli Lily & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lily & Co. (United States) Revenue: by Geography 2020
  • Figure 34. Global Biopharmaceutical: by Type USD Million (2021-2026)
  • Figure 35. Global Biopharmaceutical: by Application USD Million (2021-2026)
  • Figure 36. Global Biopharmaceutical: by Production USD Million (2021-2026)
  • Figure 37. South America Biopharmaceutical Share (%), by Country
  • Figure 38. Asia Pacific Biopharmaceutical Share (%), by Country
  • Figure 39. Europe Biopharmaceutical Share (%), by Country
  • Figure 40. MEA Biopharmaceutical Share (%), by Country
  • Figure 41. North America Biopharmaceutical Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis A.G. (Switzerland)
  • Pfizer Inc (United States)
  • Merck & Co. (United States)
  • Abbott Laboratories (United States)
  • Amgen Inc. (United States)
  • Biogen Idec (United States)
  • Bristol Myers Squibb (United States)
  • AbbVie (United States)
  • Eli Lily & Co. (United States)
Additional players considered in the study are as follows:
Johnson & Johnson (United States) , Merck & Co. Inc (United States) , GlaxoSmithKline PLC (United Kingdom) , Roche (Switzerland) ,
Select User Access Type

Key Highlights of Report


Jun 2021 233 Pages 83 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Biopharmaceutical market is predicted to grow at a CAGR of 8.6% between 2020 - 2026.
Global Biopharmaceutical market is restrained by Increasing demand for affordable biopharmaceuticals, High-end manufacturing requirements, Complicated and cumbersome regulatory requirements and Side effects of biopharmaceuticals.
Metabolic disorders is dominating end use application in Biopharmaceutical Market.

Know More About Global Biopharmaceutical Market Report?